ATE380049T1 - Kombinationen enthaltend cgmp-pde5-hemmer. - Google Patents

Kombinationen enthaltend cgmp-pde5-hemmer.

Info

Publication number: ATE380049T1
Authority: AT; Austria
Prior art keywords: combinations containing; pde5 inhibitors; containing cgmp; cgmp; pde5
Prior art date: 1999-10-21

Application number

AT04010436T

Other languages

English (en)

Inventor

Eliot Richard Forster

Nandan Parmanand Koppiker

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-21

Filing date

2000-10-17

Publication date

2007-12-15

1999-10-21 Priority claimed from GBGB9924958.3A external-priority patent/GB9924958D0/en

2000-09-01 Priority claimed from GB0021520A external-priority patent/GB0021520D0/en

2000-10-17 Application filed by Pfizer filed Critical Pfizer

2007-12-15 Application granted granted Critical

2007-12-15 Publication of ATE380049T1 publication Critical patent/ATE380049T1/de

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
229960002870 gabapentin Drugs 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
229960001233 pregabalin Drugs 0.000 abstract 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT04010436T 1999-10-21 2000-10-17 Kombinationen enthaltend cgmp-pde5-hemmer. ATE380049T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924958.3A GB9924958D0 (en)	1999-10-21	1999-10-21	Treatment of neuropathy
GB0021520A GB0021520D0 (en)	2000-09-01	2000-09-01	Treatment of neuropathy

Publications (1)

Publication Number	Publication Date
ATE380049T1 true ATE380049T1 (de)	2007-12-15

Family

ID=26244947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04010436T ATE380049T1 (de)	1999-10-21	2000-10-17	Kombinationen enthaltend cgmp-pde5-hemmer.

Country Status (16)

Country	Link
US (2)	US20030162782A1 (de)
EP (2)	EP1440709B1 (de)
JP (2)	JP2001122803A (de)
KR (1)	KR20010051181A (de)
AT (1)	ATE380049T1 (de)
AU (1)	AU781550B2 (de)
CA (1)	CA2323839C (de)
CO (1)	CO5271711A1 (de)
CY (1)	CY1107285T1 (de)
DE (1)	DE60037347T2 (de)
DK (1)	DK1440709T3 (de)
ES (1)	ES2295726T3 (de)
HU (1)	HUP0004120A3 (de)
IL (2)	IL152925A (de)
PE (1)	PE20010754A1 (de)
PT (1)	PT1440709E (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1630532A (zh) *	2000-04-19	2005-06-22	约翰斯霍普金斯大学	预防和治疗胃肠疾病的方法
FR2809623B1 (fr) *	2000-06-05	2003-09-05	Sanjuan Benito Arranz	Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1575916B1 (de)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesteraseaktivität und regulation der durch phosphodiesterase-1-b vermittelten signalvermittlung im hirn
GB0129274D0 (en) *	2001-12-06	2002-01-23	Pfizer Ltd	Novel kit
CN1638775A (zh)	2002-01-04	2005-07-13	亨利福尔德健康组织	治疗疾病和损伤用的氧化氮供体
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) *	2002-08-15	2002-09-25	Pfizer Ltd	Synergistic combinations
US7659305B2 (en)	2002-10-31	2010-02-09	Pfizer Inc.	Therapeutic proline derivatives
PT1572173E (pt) *	2002-12-13	2010-05-10	Warner Lambert Co	Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
PE20050460A1 (es)	2003-04-23	2005-07-08	Japan Tobacco Inc	COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
DE10325813B4 (de)	2003-06-06	2007-12-20	Universitätsklinikum Freiburg	Prophylaxe und/oder Therapie bei der portalen Hypertonie
ES2334682T3 (es) *	2004-03-05	2010-03-15	Nycomed Gmbh	Nuevo uso para inhibidores de pde5.
WO2006133261A2 (en)	2005-06-06	2006-12-14	Intra-Cellular Therapies, Inc.	Organic compounds
EP1919287A4 (de) *	2005-08-23	2010-04-28	Intra Cellular Therapies Inc	Organische verbindungen zur behandlung einer verringerten dopamin-rezeptorsignalisierungs-aktivität
AU2007256633B2 (en) *	2006-06-06	2013-09-12	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008063505A1 (en) *	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008131256A1 (en) *	2007-04-19	2008-10-30	Trinity Laboratories Inc.	Improved treatments for premature ejaculation in humans
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2939676A1 (de) *	2007-12-06	2015-11-04	Intra-Cellular Therapies, Inc.	Organische Verbindungen
ES2588238T3 (es) *	2007-12-06	2016-10-31	Intra-Cellular Therapies, Inc.	Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2009322903A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
PE20110922A1 (es)	2008-12-06	2012-01-22	Intra Cellular Therapies Inc	DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
MX2011005934A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
EA201170769A1 (ru) *	2008-12-06	2012-02-28	Интра-Селлулар Терапиз, Инк.	Органические соединения
AU2009322899A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (de)	2009-05-13	2013-08-07	Intra Cellular Therapies Inc	Organische verbindungen
WO2011016861A2 (en)	2009-08-05	2011-02-10	Intra-Cellular Therapies, Inc.	Novel regulatory proteins and inhibitors
EP2483281B1 (de)	2009-10-01	2014-06-04	Cymabay Therapeutics, Inc.	Substituierte tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidinsalze
WO2011143607A1 (en) *	2010-05-14	2011-11-17	The Regents Of The University Of California	Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
EP2575817A4 (de)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Organische verbindungen
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
US9763948B2 (en)	2010-05-31	2017-09-19	Intra-Cellular Therapies, Inc.	PDE1 inhibitory compounds and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
AU2011264941B2 (en) *	2010-06-07	2014-10-16	Suda Ltd	Oral spray formulations and methods for administration of sildenafil
BR112012032248A2 (pt)	2010-06-23	2016-09-13	Metabolex Inc	composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
EP2717877B1 (de)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organische verbindungen
CN102276511A (zh) *	2011-06-20	2011-12-14	兰州博实生化科技有限责任公司	1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法
US8449565B2 (en)	2011-07-21	2013-05-28	Francis Duhay	Approaches to venous occlusion for embolus management
EP2956141A4 (de)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	Neuartige verwendungen
ES2717688T3 (es)	2013-03-15	2019-06-24	Intra Cellular Therapies Inc	Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
RU2549459C2 (ru) *	2013-08-20	2015-04-27	Константин Александрович Корейба	Способ лечения нейропатических трофических язв при синдроме диабетической стопы
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
DK3157926T3 (da)	2014-06-20	2019-08-19	Intra Cellular Therapies Inc	Organiske forbindelser
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
CA2961212C (en)	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
BR112017012007B1 (pt)	2014-12-06	2022-11-01	Intra-Cellular Therapies, Inc	Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
WO2016090382A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Organic compounds
US10813894B2 (en)	2015-02-20	2020-10-27	The Regents Of The University Of California	Methods of inhibiting pain
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2018026890A1 (en)	2016-08-03	2018-02-08	Cymabay Therapeutics	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109596A1 (es)	2016-09-09	2018-12-26	Incyte Corp	Compuestos pirazolopiridina y sus usos
US20180072741A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
WO2018152220A1 (en)	2017-02-15	2018-08-23	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
MX2017016930A (es) *	2017-12-19	2019-06-20	Malesil Research & Tech Llc	Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
DK3755703T3 (da)	2018-02-20	2022-06-27	Incyte Corp	N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
WO2020068729A1 (en)	2018-09-25	2020-04-02	Incyte Corporation	Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko)	2019-08-06	2022-05-10	인사이트 코포레이션	고체 형태의 hpk1 억제제
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
EP0882718B1 (de) *	1995-12-28	2005-08-31	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazolderivate
EP0934061B3 (de) *	1996-07-24	2015-01-21	Warner-Lambert Company LLC	Isobutylgaba und dessen derivate zur schmerzbehandlung
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
ES2203078T3 (es) *	1998-04-20	2004-04-01	Pfizer Inc.	Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
US6331171B1 (en) *	1998-06-04	2001-12-18	Alcon Laboratories, Inc.	Tip for a liquefracture handpiece
GB9823103D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
GB9823101D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
ES2205945T3 (es) *	1998-10-23	2004-05-01	Pfizer Inc.	Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
US6453237B1 (en) *	1999-04-23	2002-09-17	Global Locate, Inc.	Method and apparatus for locating and providing services to mobile devices
US6411892B1 (en) *	2000-07-13	2002-06-25	Global Locate, Inc.	Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris
IL137429A0 (en) *	1999-07-28	2001-07-24	Pfizer Prod Inc	Methods and compsitions for treating diseases and conditions of the eye
ES2272297T3 (es) *	1999-10-12	2007-05-01	Lilly Icos Llc	Medicamento destinado al tratamiento de neuropatias.
US7196660B2 (en) *	2000-11-17	2007-03-27	Global Locate, Inc	Method and system for determining time in a satellite positioning system
US6560534B2 (en) *	2001-06-06	2003-05-06	Global Locate, Inc.	Method and apparatus for distributing satellite tracking information

2000
- 2000-10-16 IL IL152925A patent/IL152925A/en not_active IP Right Cessation
- 2000-10-16 IL IL13907300A patent/IL139073A0/xx unknown
- 2000-10-17 ES ES04010436T patent/ES2295726T3/es not_active Expired - Lifetime
- 2000-10-17 PT PT04010436T patent/PT1440709E/pt unknown
- 2000-10-17 EP EP04010436A patent/EP1440709B1/de not_active Expired - Lifetime
- 2000-10-17 DK DK04010436T patent/DK1440709T3/da active
- 2000-10-17 DE DE60037347T patent/DE60037347T2/de not_active Expired - Fee Related
- 2000-10-17 AT AT04010436T patent/ATE380049T1/de not_active IP Right Cessation
- 2000-10-17 EP EP00309129A patent/EP1129706A3/de not_active Withdrawn
- 2000-10-19 CA CA002323839A patent/CA2323839C/en not_active Expired - Fee Related
- 2000-10-20 CO CO00080163A patent/CO5271711A1/es not_active Application Discontinuation
- 2000-10-20 AU AU66650/00A patent/AU781550B2/en not_active Withdrawn - After Issue
- 2000-10-20 HU HU0004120A patent/HUP0004120A3/hu unknown
- 2000-10-20 PE PE2000001133A patent/PE20010754A1/es not_active Application Discontinuation
- 2000-10-21 KR KR1020000062129A patent/KR20010051181A/ko not_active Ceased
- 2000-10-23 JP JP2000322510A patent/JP2001122803A/ja active Pending
2002
- 2002-07-26 US US10/206,615 patent/US20030162782A1/en not_active Abandoned
- 2002-10-10 JP JP2002297617A patent/JP2003119131A/ja active Pending
2003
- 2003-12-10 US US10/731,905 patent/US20040122010A1/en not_active Abandoned
2008
- 2008-02-18 CY CY20081100193T patent/CY1107285T1/el unknown

Also Published As

Publication number	Publication date
CA2323839C (en)	2008-03-18
EP1129706A3 (de)	2002-01-02
US20030162782A1 (en)	2003-08-28
JP2003119131A (ja)	2003-04-23
PT1440709E (pt)	2008-02-06
PE20010754A1 (es)	2001-07-18
JP2001122803A (ja)	2001-05-08
EP1440709A2 (de)	2004-07-28
HUP0004120A3 (en)	2003-11-28
DE60037347D1 (de)	2008-01-17
KR20010051181A (ko)	2001-06-25
IL139073A0 (en)	2001-11-25
CA2323839A1 (en)	2001-04-21
US20040122010A1 (en)	2004-06-24
EP1440709B1 (de)	2007-12-05
AU781550B2 (en)	2005-05-26
EP1129706A2 (de)	2001-09-05
DE60037347T2 (de)	2008-11-27
EP1440709A3 (de)	2004-12-08
HU0004120D0 (de)	2001-01-29
IL152925A (en)	2010-04-15
HUP0004120A2 (hu)	2002-11-28
AU6665000A (en)	2001-04-26
ES2295726T3 (es)	2008-04-16
DK1440709T3 (da)	2008-03-17
CO5271711A1 (es)	2003-04-30
CY1107285T1 (el)	2012-11-21

Legal Events

Date

Code

Title

Description

2008-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1440709

Country of ref document: EP

2010-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60037347D1 (de)	2008-01-17	Kombinationen enthaltend cGMP-PDE5-hemmer.
BR0108750A (pt)	2002-12-24	Variantes da xilanase que apresentam sensibilidade alterada para inibidores da xilanase
PL371515A1 (en)	2005-06-27	Hif hydroxylase inhibitors
ECSP034600A (es)	2003-06-25	Compuestos de lactama
GB2379798B (en)	2003-07-30	Light emitting diode and method for manufacturing the same
ZA9811595B (en)	2000-06-19	Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors.
BR0102059B1 (pt)	2009-05-05	segmento retentor para conjunto turbilhonador.
DE60135387D1 (de)	2008-09-25	7,9 substituierte tetracyclinverbindungen
GB0120993D0 (en)	2001-10-24	Pulsed UV light source
MXPA02012494A (es)	2003-04-25	Tiazina oxazolidinona.
WO2002014925A3 (en)	2003-04-03	Lamp structure, having elliptical reflectors, for uniformly irradiating surfaces of optical fiber and method of use thereof
DK0840606T3 (da)	2000-08-07	Små di- og trivalente molekyler som selectininhibitorer
ITTO20021024A1 (it)	2003-06-11	Trattamento di superficie per componenti ferrosi.
GB0011358D0 (en)	2000-06-28	Novel use
PT941975E (pt)	2002-06-28	Cimento para injeccao contendo inibidores de corrosao
PT1007109E (pt)	2003-08-29	Adesivo para tecidos a base de fibrinogenio
NZ320259A (en)	1999-06-29	Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
EA200601466A1 (ru)	2006-12-29	Новые комбинации противорвотного агента и ингибитора энкефалиназы
MY138266A (en)	2009-05-29	Treatment of neuropathy
DK1188681T3 (da)	2005-03-14	Beskyttelsesemballage til en cylindrisk genstand, forsynet med et fastgörelsesmiddel
MY140504A (en)	2009-12-31	Statin-mmp inhibitor combinations
BR0210678A (pt)	2004-09-21	Carbamatos de 2-heterocìclicos-1,2-etanodióis
GB0113920D0 (en)	2001-08-01	Composition
WO1999066609A3 (de)	2000-01-27	Lichtquelle, mit einem ein gas einschliessenden hohlraum
ZA200205460B (en)	2003-03-18	A light source.